Growth inhibition and apoptosis due to rituximab alone
| Cell line . | Growth inhibition, % . | P . | Rituximab, % annexin V+ cells . | Rituximab-induced sub-G1DNA . |
|---|---|---|---|---|
| DHL-4 | 54 | < .0001 | 23 | Weak |
| Daudi | 24 | .025 | 13 | Weak |
| FL-18 | 17 | NS | 12 | No |
| Granta 519 | 20 | .005 | 7 | No |
| NCEB-1 | 30 | .002 | 7 | No |
| OCI Ly8 | 42 | .003 | 5 | No |
| Raji | 13 | NS | 12 | No |
| Ramos | 18 | .002 | 7 | No |
| Tab | 83 | .0001 | 17 | Weak |
| Cell line . | Growth inhibition, % . | P . | Rituximab, % annexin V+ cells . | Rituximab-induced sub-G1DNA . |
|---|---|---|---|---|
| DHL-4 | 54 | < .0001 | 23 | Weak |
| Daudi | 24 | .025 | 13 | Weak |
| FL-18 | 17 | NS | 12 | No |
| Granta 519 | 20 | .005 | 7 | No |
| NCEB-1 | 30 | .002 | 7 | No |
| OCI Ly8 | 42 | .003 | 5 | No |
| Raji | 13 | NS | 12 | No |
| Ramos | 18 | .002 | 7 | No |
| Tab | 83 | .0001 | 17 | Weak |
Columns 1 and 2 demonstrate the percentage of growth inhibition induced by saturating doses of rituximab (10 μg/mL) and the corresponding P values, derived from 3 or more separate experiments. Growth inhibition was calculated as 1 − experimental CPM divided by control CPM, and growth inhibition was reported as a percentage with the highest (least significant) Pvalue. Two cell lines, FL-18 and Raji, had insignificant growth inhibition, whereas in all other cell lines, growth inhibition was highly statistically significant. Column 3 summarizes the mean percentage of cells (taken from at least 3 experiments) that become annexin V+ (minus control) following treatment with 48 hours of rituximab (10 μg/mL). Results range from 5% to 23% of cells. Column 4 summarizes the effects of rituximab alone on DNA fragmentation. Three cell lines, following exposure to rituximab (10 μg/mL) for 72 hours, have weak, but reproducible and statistically significant, increases in sub-G1 DNA content.
NS indicates not significant.